Showing 2 results for Empagliflozin
Parisa Dana, Nasim Hayati Rodbari, Parichehreh Yaghmaei, Zahra Haj Ebrahimi,
Volume 21, Issue 4 (10-2021)
Abstract
Background: Empagliflozin, selective glucose-sodium inhibitor of the latest drugs in the treatment of type 2 diabetes. Diabetes induced hypogonadism disrupts sexual function. There is a direct relationship between reducing blood glucose and reduced libido. In this project, the anti-diabetic drug Empagliflozin in addition to treatment has been studied, in terms of effect on sexual function.
Methods: Type 2 diabetes with injection of 60 mg/kg streptozotocin per body weight was create intraperitoneally. The primary diabetes was treated with two doses of 10 and 25 mg/kg Empagliflozin per body weight. Sexual hormones, biochemical parameters and lipid profile were measured. Evaluation of Sperm parameters and morphological studies were performed on testicular tissue, pancreas and epididymis. Data were analyzed by one-way ANOVA in SPSS software version 22 and P˂0.05 was considered as a significant level.
Results: Empagliflozin significantly increases the quality, survival and natural state of sperm head and tail. Empagliflozin reduces weight in diabetic rats. Empagliflozin Without increasing hyperglycemia by reducing blood glucose affects steroidogenesis, maintains fertility strength in testicles, and increases the level of sex hormones. Empagliflozin significantly increases insulin secretion. Empagliflozin maintains and integrity of pancreatic beta cells. Empagliflozin has no effect on lipid profile.
Conclusion: Empagliflozin in addition positive effects on the treatment of diabetes in the early stage improves sexual function in adult rats.
Eftekhar Mohammadi, Mohammad Fathi, Farzaneh Chehelcheragi, Afshin Nazari,
Volume 22, Issue 1 (4-2022)
Abstract
Background: The aim of this study was to evaluate the effect of eight weeks of endurance training and Empagliflozin consumption on inflammatory markers and their relationship with heart structure and function of diabetic male Rats.
Methods: 40 male Wistar rats were randomly divided into five groups: healthy control, diabetic control, diabetic + empagliflozin, diabetic + endurance training and diabetic + endurance training + empagliflozin. The groups were anesthetized and their cardiac function and TNF-α and TGF-β indices were evaluated by one-way ANOVA and Pearson correlation tests after performing the training protocol and receiving medication.
Results: There were significant differences in left ventricular end systolic thickness (P = 0.011), left ventricular end systolic volume (P = 0.008), TNF-α (P = 0.014) and TGF-β (P = 0.001) was observed between the research groups. Also, there was a significant negative relationship between TGF-β with body weight, heart fiber shortening percentage and injection fraction and a significant positive relationship with glucose levels, left ventricular end systolic thickness and left ventricular end systolic volume. In addition, a significant negative correlation was observed between TGF-β and the injection fraction (P≤0.05).
Conclusion: Aerobic exercise seems to improve the inflammatory status, structure and function of diabetic heart tissue beyond the dual effect of Empagliflozin.
